MedPath

Comparison of Deferazirox and Deferoxamine on Serum Ferritin Levels Changes in Major Beta Thalassemia Patients

Not Applicable
Conditions
beta thalassemia major.
Beta thalassemia
D56.1
Registration Number
IRCT20190817044550N4
Lead Sponsor
Birjand University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
45
Inclusion Criteria

The age of the patients was 2 years and older
Have a normal serum creatinine level
Absence of proteinuria in U/A patients
The serum ferritin levels of the patients should be above 1000 mg/dl, or the patients should have had more than 10 blood transfusions, or the volume of blood transferred should be more than 100 cc/kg

Exclusion Criteria

Pregnancy and breastfeeding
Resistant levels greater than 5 times the normal value of liver transaminase
Severe nausea and vomiting in the patient
Patient refusal to participate in the study

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum ferritin level. Timepoint: Measurement of serum ferritin level at the beginning of the study (before the start of the intervention), 3 and 6 months after the start of the intervention. Method of measurement: Biochemical test.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath